The Float Is Razor Thin
Chart Is Trending Bullish
Substantial Market Opportunity
Strong And Growing Patent Portfolio
Plans To Uplist
Expected FDA 510(k) Submission For 2nd Product
Majority of NeuroOne’s products expect US FDA 501 process.
Comapny Profile
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, essential tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Why NeuroOne?
NeuroOne (OTCQB:NMTC) is a next generation electrode technology company specializing in development and commercialization of hi-definition thin film electrodes for the diagnosis and
treatment of various neurological conditions such as epilepsy, Parkinson’s Disease
and chronic pain due to failed back surgery syndrome
First FDA 510(k) clearance for cortical electrode product family December 2019
Potential ability to perform recording, ablation and stimulation with the same electrode
Minimally invasive flexible patented technology leverages printed circuit technology
We expect our technology could reduce manufacturing costs, procedural costs and improve patient outcomes
Mayo Clinic assisted in the development process, successfully used devices in humans as part of a research protocol and currently maintains an ownership position in the Company. WARF (University of Madison-Wisconsin’s Alumni Research Foundation) also assisted in development)
Well positioned electrode technology has strong potential for future use in DBS (deep brain stimulation) spinal cord stimulation and artificial intelligence applications, which may play an important future role in treating patients with more complex neurological issues
Experienced Management Team, Board of Directors and two Advisory Boards with highly acclaimed physicians from prestigious institutions
Strong and growing patent portfolio(MI tool, drug delivery, spinal cord stim )
The Bottom Line
With its low-float and recent announcements, we believe that NMTC is in for a huge day of trading.
The Company is in the midst of a major growth period, and we believe it has the potential to double in price from here.
Having been granted the regulatory green light to begin bringing its product line to market, Neuro-One’s stock is still ranging within its lows (currently at around $2.00 per share). This shouldn’t come as a surprise, as the emerging healthcare space is often too specialized a sub-industry for most mainstream investors to monitor let alone understand.
But for the few who can grasp both the relevance and growth potential of Neuro-One’s product line, the company offers early investors an opportunity to get in on a much-needed medical product that, to date, sees neither comparable solutions nor formidable competition.
Traders looking for a company that is committed to growth, and with plenty of upside should add NMTC to the top of their watchlist immediately..By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Chart Is Trending Bullish
Substantial Market Opportunity
Strong And Growing Patent Portfolio
Plans To Uplist
Expected FDA 510(k) Submission For 2nd Product
Majority of NeuroOne’s products expect US FDA 501 process.
Comapny Profile
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, essential tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Why NeuroOne?
NeuroOne (OTCQB:NMTC) is a next generation electrode technology company specializing in development and commercialization of hi-definition thin film electrodes for the diagnosis and
treatment of various neurological conditions such as epilepsy, Parkinson’s Disease
and chronic pain due to failed back surgery syndrome
First FDA 510(k) clearance for cortical electrode product family December 2019
Potential ability to perform recording, ablation and stimulation with the same electrode
Minimally invasive flexible patented technology leverages printed circuit technology
We expect our technology could reduce manufacturing costs, procedural costs and improve patient outcomes
Mayo Clinic assisted in the development process, successfully used devices in humans as part of a research protocol and currently maintains an ownership position in the Company. WARF (University of Madison-Wisconsin’s Alumni Research Foundation) also assisted in development)
Well positioned electrode technology has strong potential for future use in DBS (deep brain stimulation) spinal cord stimulation and artificial intelligence applications, which may play an important future role in treating patients with more complex neurological issues
Experienced Management Team, Board of Directors and two Advisory Boards with highly acclaimed physicians from prestigious institutions
Strong and growing patent portfolio(MI tool, drug delivery, spinal cord stim )
The Bottom Line
With its low-float and recent announcements, we believe that NMTC is in for a huge day of trading.
The Company is in the midst of a major growth period, and we believe it has the potential to double in price from here.
Having been granted the regulatory green light to begin bringing its product line to market, Neuro-One’s stock is still ranging within its lows (currently at around $2.00 per share). This shouldn’t come as a surprise, as the emerging healthcare space is often too specialized a sub-industry for most mainstream investors to monitor let alone understand.
But for the few who can grasp both the relevance and growth potential of Neuro-One’s product line, the company offers early investors an opportunity to get in on a much-needed medical product that, to date, sees neither comparable solutions nor formidable competition.
Traders looking for a company that is committed to growth, and with plenty of upside should add NMTC to the top of their watchlist immediately..By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)